This Is MS Multiple Sclerosis Community: Knowledge & Support

Novartis published first quarter results today. The following info was provided on FTY720:

FTY720 (fingolimod), an oral once-daily treatment for relapsing forms of multiple sclerosis (MS), is currently in Phase III development. Discussions are continuing with the FDA on starting a Phase III study in the US. Data from an extension of a Phase II trial to 18 months presented in April confirmed the substantial efficacy of FTY720 in significantly reducing the relapse rate and inflammatory disease activity of patients with this disease.

Good morning Bromley,
I too have been following the trail and trials of FTY720. Curious as to why such a large number of volunteers dropped out of the trial for reasons given as "other' and not pertaining to adverse effects of the drug being tested. Any ideas? How would one find out?
Lynne